Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn:
“Out in JCO the groundbreaking results (previously presented during ASCO24 by Natasha Leighl) of the randomized phase 3 trial PALOMA-3 study, which evaluated subcutaneous (SC) amivantamab combined with lazertinib in pretreated patients with EGFR-mutant NSCLC.
Remarkably, SC amivantamab, with just a 5-minute infusion time, demonstrated non-inferior efficacy and pharmacokinetics compared to intravenous (IV) administration, while reducing infusion-related reactions (IRRs) by five times.
This is a significant step forward for our patients and a revolutionary advancement in the treatment landscape for NSCLC with EGFR mutations.
Honored to have been part of this significant milestone.”
View the article attached to the post.
Source: Antonio Passaro/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023